Anticoagulant Classes and Mechanisms

Mechanism of Action and Classification

Argatroban is a direct thrombin inhibitor that binds noncovalently to the active site of thrombin, selectively inhibiting both free and clot-bound thrombin without requiring a cofactor, according to the American College of Chest Physicians 2
The American College of Chest Physicians and Anaesthesia guidelines explicitly categorize argatroban and Xarelto as distinct drug classes within the direct oral anticoagulant (DOAC) family, with direct thrombin inhibitors including dabigatran and argatroban, and direct Factor Xa inhibitors including rivaroxaban, apixaban, and edoxaban 1, 3

Argatroban has a plasma half-life of 45 minutes with rapid onset and offset, is metabolized in the liver via cytochrome P450 3A4/5 enzyme system, and is particularly useful in patients with severe renal impairment because it is not renally excreted, as recommended by the American College of Chest Physicians 2
The American College of Chest Physicians recommends that argatroban requires continuous IV infusion with aPTT monitoring targeting 1.5-2.5 times baseline 2

The American College of Anaesthesia guidelines state that the different mechanisms of action of argatroban and Xarelto mean these drugs are not interchangeable and have distinct clinical roles, with argatroban primarily used for heparin-induced thrombocytopenia (HIT) as parenteral therapy, and Xarelto used for atrial fibrillation, venous thromboembolism treatment/prevention, and acute coronary syndromes as oral therapy 1, 3, 4
The American College of Anaesthesia guidelines recommend that in HIT management, argatroban can be transitioned to rivaroxaban once platelet recovery occurs, demonstrating they serve complementary rather than equivalent roles 1, 3